Dr Russell J Munson, MD | |
15 Spring St, Chester, CT 06412-1338 | |
(860) 526-2548 | |
(860) 526-4043 |
Full Name | Dr Russell J Munson |
---|---|
Gender | Male |
Speciality | Family Medicine |
Location | 15 Spring St, Chester, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1619956760 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 023004 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Russell J Munson, MD 15 Spring St, Chester, CT 06412-1338 Ph: (860) 526-2548 | Dr Russell J Munson, MD 15 Spring St, Chester, CT 06412-1338 Ph: (860) 526-2548 |
News Archive
When contact lenses work really well, you forget they are on your eyes. You might not feel the same at the end of a long day staring at a computer screen. After too many hours of wear, the lenses and your eyes dry out, causing irritation that might outweigh the convenience of contacts.
A new study sheds light on how the immune system replenishes itself during sleep. Researchers found that some subsets of T cells are reduced from the bloodstream during sleep when risk of infection is low.
Abbott today announced the European approval and launch of its TREKā¢ Coronary Dilatation Catheter for the treatment of coronary artery disease. The TREK system represents a new approach to balloon catheter design, and provides physicians with a high-performing option for treating challenging lesions and difficult-to-reach blockages. Abbott received CE Mark for the TREK system earlier this year.
Waters Corporation today launched a new program to support scientific innovation in the fields of health and life science research, sports science, food safety, clinical research and environmental protection.
pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).
› Verified 8 days ago